A Study of Azidothymidine Plus Methadone in Patients With AIDS and AIDS Related Complex (ARC)
Information source: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV Infections
Intervention: Methadone hydrochloride (Drug); Zidovudine (Drug)
Phase: N/A
Status: Completed
Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID) Official(s) and/or principal investigator(s):
G Friedland, Study Chair
Summary
To determine if methadone treatment will affect the blood levels of zidovudine (AZT) in
patients with AIDS or AIDS-related complex (ARC) who are receiving oral AZT and methadone
therapy. In addition, the blood levels of methadone both before and during AZT treatment
will be studied, and patients receiving daily oral methadone treatment will be evaluated for
signs of narcotic withdrawal during treatment with AZT.
The number of deaths due to AIDS in high-risk populations continues to increase. Nationwide
approximately 25 percent of AIDS patients are intravenous (IV) drug abusers, and it is very
likely that an increasingly larger number of AIDS patients receiving AZT therapy will have
had a history of IV drug abuse. The major chemical treatment for IV drug abuse is daily
methadone maintenance therapy, and IV drug abusers who are HIV positive represent a large
number of patients who will undergo long-term treatment with both methadone and AZT.
Therefore, the study of potential drug interactions is essential.
Clinical Details
Official title: Pharmacokinetic Study of the Interaction of Azidothymidine and Methadone in Patients With AIDS and ARC
Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment
Detailed description:
The number of deaths due to AIDS in high-risk populations continues to increase. Nationwide
approximately 25 percent of AIDS patients are intravenous (IV) drug abusers, and it is very
likely that an increasingly larger number of AIDS patients receiving AZT therapy will have
had a history of IV drug abuse. The major chemical treatment for IV drug abuse is daily
methadone maintenance therapy, and IV drug abusers who are HIV positive represent a large
number of patients who will undergo long-term treatment with both methadone and AZT.
Therefore, the study of potential drug interactions is essential.
The 18 patients are patients with AIDS or ARC. Nine are control patients who are not
receiving methadone and are not IV drug abusers. Nine are former IV drug abusers who have
been maintained on methadone for at least 6 months and who have been receiving a constant
daily dose of methadone for at least 1 month. Plasma and urine levels of methadone are
determined over a 4 hour period. The dose of AZT: For the pharmacokinetic study of AZT,
plasma and urine samples are taken after oral dose of AZT and an intravenous dose of AZT in
the control and methadone groups.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria
Prior Medication:
Allowed:
- Oral nonabsorbable antifungal agents.
The study will include 18 patients with AIDS or HIV-related symptomatic illness as defined
by the CDC classification group IVa and c2. Of these, 9 methadone recipients will have
been maintained on methadone for at least 1 month and will have received a constant daily
dose of 30-90 mg of methadone for at least 10 days.
Nine patients will be former intravenous drug abusers.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Temperature > 101 degrees F.
- Ascites.
- Active opportunistic infection.
Concurrent Medication:
Excluded:
- Other inducers or inhibitors of hepatic microsomal enzymes.
- Any chronic systemic medications.
Patients with the following symptoms or conditions are excluded:
- Temperature > 101 degrees F.
- Ascites.
- Active opportunistic infection.
Prior Medication:
Excluded within 72 hours of study entry:
- All medication except oral nonabsorbable antifungal agents.
- Excluded within 2 weeks of study entry:
- Any other experimental drug.
- Drugs with known nephrotoxic potential or drugs known to cause neutropenia.
- Rifampin or its derivatives, phenytoin, or barbiturates.
Active drug or alcohol abuse.
Locations and Contacts
Montefiore Med Ctr / Bronx Municipal Hosp, Bronx, New York 10467, United States
Additional Information
Click here for more information about Zidovudine
Related publications: Schwartz EL, Brechbuhl AB, Kahl P, Miller MH, Selwyn PA, Friedland GH. Altered pharmacokinetics of zidovudine in former IV drug-using patients receiving methadone. Int Conf AIDS. 1990 Jun 20-23;6(3):194 (abstract no SB432) Schwartz EL, Brechbühl AB, Kahl P, Miller MA, Selwyn PA, Friedland GH. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. J Acquir Immune Defic Syndr. 1992;5(6):619-26.
Last updated: March 11, 2011
|
